Search Results - (Author, Cooperation:S. Vermeire)
-
1Latest Papers from Table of Contents or Articles in PressL. Jostins ; S. Ripke ; R. K. Weersma ; R. H. Duerr ; D. P. McGovern ; K. Y. Hui ; J. C. Lee ; L. P. Schumm ; Y. Sharma ; C. A. Anderson ; J. Essers ; M. Mitrovic ; K. Ning ; I. Cleynen ; E. Theatre ; S. L. Spain ; S. Raychaudhuri ; P. Goyette ; Z. Wei ; C. Abraham ; J. P. Achkar ; T. Ahmad ; L. Amininejad ; A. N. Ananthakrishnan ; V. Andersen ; J. M. Andrews ; L. Baidoo ; T. Balschun ; P. A. Bampton ; A. Bitton ; G. Boucher ; S. Brand ; C. Buning ; A. Cohain ; S. Cichon ; M. D'Amato ; D. De Jong ; K. L. Devaney ; M. Dubinsky ; C. Edwards ; D. Ellinghaus ; L. R. Ferguson ; D. Franchimont ; K. Fransen ; R. Gearry ; M. Georges ; C. Gieger ; J. Glas ; T. Haritunians ; A. Hart ; C. Hawkey ; M. Hedl ; X. Hu ; T. H. Karlsen ; L. Kupcinskas ; S. Kugathasan ; A. Latiano ; D. Laukens ; I. C. Lawrance ; C. W. Lees ; E. Louis ; G. Mahy ; J. Mansfield ; A. R. Morgan ; C. Mowat ; W. Newman ; O. Palmieri ; C. Y. Ponsioen ; U. Potocnik ; N. J. Prescott ; M. Regueiro ; J. I. Rotter ; R. K. Russell ; J. D. Sanderson ; M. Sans ; J. Satsangi ; S. Schreiber ; L. A. Simms ; J. Sventoraityte ; S. R. Targan ; K. D. Taylor ; M. Tremelling ; H. W. Verspaget ; M. De Vos ; C. Wijmenga ; D. C. Wilson ; J. Winkelmann ; R. J. Xavier ; S. Zeissig ; B. Zhang ; C. K. Zhang ; H. Zhao ; M. S. Silverberg ; V. Annese ; H. Hakonarson ; S. R. Brant ; G. Radford-Smith ; C. G. Mathew ; J. D. Rioux ; E. E. Schadt ; M. J. Daly ; A. Franke ; M. Parkes ; S. Vermeire ; J. C. Barrett ; J. H. Cho
Nature Publishing Group (NPG)
Published 2012Staff ViewPublication Date: 2012-11-07Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Colitis, Ulcerative/genetics/immunology/microbiology/physiopathology ; Crohn Disease/genetics/immunology/microbiology/physiopathology ; Genetic Predisposition to Disease/*genetics ; Genome, Human/genetics ; *Genome-Wide Association Study ; Haplotypes/genetics ; *Host-Pathogen Interactions/genetics/immunology ; Humans ; Inflammatory Bowel Diseases/*genetics/immunology/*microbiology/physiopathology ; Mycobacterium/*immunology/pathogenicity ; Mycobacterium Infections/genetics/microbiology ; Mycobacterium tuberculosis/immunology/pathogenicity ; Phenotype ; Polymorphism, Single Nucleotide/genetics ; Reproducibility of ResultsPublished by: -
2Latest Papers from Table of Contents or Articles in PressVan Stappen, T., Vande Casteele, N., Van Assche, G., Ferrante, M., Vermeire, S., Gils, A.
BMJ Publishing Group
Published 2018Staff ViewPublication Date: 2018-04-07Publisher: BMJ Publishing GroupPrint ISSN: 0017-5749Electronic ISSN: 1468-3288Topics: MedicinePublished by: -
3Latest Papers from Table of Contents or Articles in PressBisschops, R., Bessissow, T., Joseph, J. A., Baert, F., Ferrante, M., Ballet, V., Willekens, H., Demedts, I., Geboes, K., De Hertogh, G., Vermeire, S., Rutgeerts, P., Van Assche, G.
BMJ Publishing Group
Published 2018Staff ViewPublication Date: 2018-05-09Publisher: BMJ Publishing GroupPrint ISSN: 0017-5749Electronic ISSN: 1468-3288Topics: MedicineKeywords: GutPublished by: -
4Articles: DFG German National LicensesFranchimont, N. ; Putzeys, V. ; Collette, J. ; Vermeire, S. ; Rutgeerts, P. ; De Vos, M. ; Van Gossum, A. ; Franchimont, D. ; Fiasse, R. ; Pelckmans, P. ; Malaise, M. ; Belaiche, J. ; Louis, E.
Oxford, UK : Blackwell Science Ltd
Published 2004Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background : Crohn's disease is associated with low bone mineral density and altered bone metabolism.Aim : To assess the evolution of bone metabolism in Crohn's disease patients treated with infliximab.Methods : We studied 71 Crohn's disease patients treated for the first time with infliximab for refractory Crohn's disease. Biochemical markers of bone formation (type-I procollagen N-terminal propeptide, bone-specific alkaline phosphatase, osteocalcin) and of bone resorption (C-telopeptide of type-I collagen) were measured in the serum before and 8 weeks after infliximab therapy and compared with values in a matched healthy control group.Results : Eight weeks after treatment with infliximab, a normalization of bone markers was observed with a median increase in formation markers of 14–51% according to marker and a lower but significant decrease in resorption marker (median 11%). A clinically relevant increase in bone formation markers was present in 30–61% of patients according to the marker. A clinically relevant decrease in C-telopeptide of type-I collagen was present in 38% of patients. No association was found with any tested demographic or clinical parameter.Conclusion : Infliximab therapy in Crohn's disease may rapidly influence bone metabolism by acting either on bone formation or bone resorption. This improvement seems to be independent of clinical response to infliximab.Type of Medium: Electronic ResourceURL: -
5Articles: DFG German National LicensesMarchal, L. ; D'Haens, G. ; Van Assche, G. ; Vermeire, S. ; Noman, M. ; Ferrante, M. ; Hiele, M. ; Bueno De Mesquita, M. ; D'Hoore, A. ; Penninckx, F. ; Rutgeerts, P.
Oxford, UK : Blackwell Science Ltd
Published 2004Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background : By temporarily suppressing the immune response, the anti-tumour necrosis factor agent, infliximab, may increase the risk of peri-operative complications.Aim : To test this hypothesis for intestinal resection in a cohort of 313 Crohn's disease patients treated with infliximab. Forty received one or more infusions prior to intestinal resection (31/40 within 12 weeks).Methods : The post-operative events of these patients were compared with those of a control group (infliximab naive) of 39 patients adjusted for age, gender and surgical procedure. Early (10 days) and late (3 months) major or minor complications were identified.Results : The incidence of early minor (15.0% vs. 12.8%) and major (12.5% vs. 7.7%) and late minor (2.5% vs. 5.1%) and major (17.5% vs. 12.8%) complications and the mean hospital stay after surgery (10.3 ± 4.0 days vs. 9.9 ± 5.5 days) were similar in both groups. A trend towards an increased early infection rate was found in infliximab pre-treated patients (6 vs. 1; P = 0.10), but more patients in this group received corticosteroids and/or immunosuppressives (29 vs. 16 patients; P 〈 0.05).Conclusion : The use of infliximab before intestinal resection does not prolong the hospital stay and does not increase the rate of post-operative complications.Type of Medium: Electronic ResourceURL: -
6Articles: DFG German National LicensesPERSOONS, P. ; VERMEIRE, S. ; DEMYTTENAERE, K. ; FISCHLER, B. ; VANDENBERGHE, J. ; VAN OUDENHOVE, L. ; PIERIK, M. ; HLAVATY, T. ; VAN ASSCHE, G. ; NOMAN, M. ; RUTGEERTS, P.
Oxford, UK : Blackwell Science Ltd
Published 2005Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background: Major depressive disorder is the most common psychiatric diagnosis in Crohn's disease. In other chronic diseases, evidence suggests that depression influences the course of the disease. Strong evidence of such a mediating role of major depressive disorder in Crohn's disease has never been found.Aim: To assess the relationship between major depressive disorder and outcome of treatment of luminal Crohn's disease with infliximab.Methods: In this prospective study, 100 consecutive unselected patients underwent assessment of psychosocial, demographical disease-related biological and clinical parameters at baseline and at 4 weeks after infliximab. Major depressive disorder was diagnosed using the Patient Health Questionnaire. Subsequently, the patients were followed up clinically until the next flare or during 9 months.Results: The Crohn's disease responded in 75% of the patients, and remission was achieved in 60%. The presence of major depressive disorder at baseline predicted a lower remission rate (OR = 0.166, 95% CI = 0.049–0.567, P = 0.004). At follow-up, 88% of the patients needed retreatment. At univariate regression analysis, major depressive disorder significantly decreased time to retreatment (P = 0.001). Multivariate Cox regression confirmed major depressive disorder as an independent determinant of active disease both at baseline and at re-evaluation (hazard ratio = 2.271, 95% CI: 1.36–3.79, P = 0.002).Conclusion: Major depressive disorder is a risk factor for failure to achieve remission with infliximab and for earlier retreatment in patients with active luminal Crohn's disease. Assessment and management of major depressive disorder should be part of the clinical approach to patients with Crohn's disease.Type of Medium: Electronic ResourceURL: -
7Articles: DFG German National LicensesPierik, M. ; Vermeire, S. ; Steen, K. V. ; Joossens, S. ; Claessens, G. ; Vlietinck, R. ; Rutgeerts, P.
Oxford, UK : Blackwell Science Ltd
Published 2004Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background : The role of tumour necrosis factor-α in the pathogenesis of inflammatory bowel disorders is well-known and is underscored by the effectiveness of antitumour necrosis factor-α treatment. Tumour necrosis factor-α exerts its effect by binding TNFR1 and TNFR2, which genes map to inflammatory bowel disorders susceptibility loci.Aims and methods : Since TNFR1 and TNFR2 are good candidate genes for inflammatory bowel disorders, we studied the functional TNFR2T587G and the TNFR1A36G mutation in 344 Crohn's disease and 152 ulcerative colitis patients and investigated the relation with disease phenotypes. An association with response to infliximab was evaluated in 166 Crohn's disease patients.Results : The TNFR2 587G allele was more frequent in ulcerative colitis compared with controls (P = 0.03). Both single nucleotide polymorphisms were negatively associated with smoking at diagnosis in Crohn's disease (TNFR1A36G odds ratio: 0.614, 95% confidence interval: 0.452, 0.99 and TNFR2T587G odds ratio: 0.572, 95% confidence interval: 0.820, 0.875). There was a positive association between pancolitis and the TNFR1A36G polymorphism in ulcerative colitis (odds ratio: 5.341, 95% confidence interval: 1.484, 19.39). The biological response to infliximab was lower in patients carrying TNFR1 36G (odds ratio: 0.47, 95% confidence interval: 0.234, 0.946).Conclusion : The TNFR2 587G allele was more frequent in ulcerative colitis. Both single nucleotide polymorphisms were negatively associated with smoking in Crohn's disease. A relation between TNFR1A36G and pancolitis was found in ulcerative colitis. There was no clear effect of the polymorphisms on infliximab response although, the TNFR1 minor was associated with a lower response to infliximab.Type of Medium: Electronic ResourceURL: -
8Articles: DFG German National LicensesLouis, E. ; El Ghoul, Z. ; Vermeire, S. ; Dall'Ozzo, S. ; Rutgeerts, P. ; Paintaud, G. ; Belaiche, J. ; De Vos, M. ; Van Gossum, A. ; Colombel, J. -F. ; Watier, H.
Oxford, UK : Blackwell Science Ltd
Published 2004Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Aim : To test the hypothesis of an association between polymorphism in FCGR3A (the gene coding for FcγRIIIa, which is expressed on macrophages and natural killer cells, is involved in antibody-dependent cell-mediated cytotoxicity and has recently been associated with a positive response to rituximab, a recombinant immunoglobulin G1 antibody used in non-Hodgkin's lymphomas) and response to infliximab in Crohn's disease.Methods : FCGR3A-158 polymorphism was determined using an allele-specific polymerase chain reaction assay in 200 Crohn's disease patients who had received infliximab for either refractory luminal (n = 142) or fistulizing (n = 58) Crohn's disease. Clinical and biological responses (according to C-reactive protein levels) were assessed in 200 and 145 patients, respectively.Results : There were 82.9% clinical responders in V/V patients vs. 72.7% in V/F and F/F patients (N.S.). Globally, the decrease in C-reactive protein was significantly higher in V/V patients than in F carriers (P = 0.0078). A biological response was observed in 100% of V/V patients, compared with 69.8% of F carriers (P = 0.0002; relative risk, 1.43; 95% confidence interval, 1.27–1.61). In the sub-group of patients with elevated C-reactive protein before treatment, the multivariate analysis selected the use of immunosuppressive drugs and FCGR3A genotype as independent factors influencing the clinical response to infliximab (P = 0.003).Conclusion : Crohn's disease patients with FCGR3A-158 V/V genotype have a better biological and, possibly, clinical response to infliximab.Type of Medium: Electronic ResourceURL: -
9Articles: DFG German National LicensesHLAVATY, T. ; PIERIK, M. ; HENCKAERTS, L. ; FERRANTE, M. ; JOOSSENS, S. ; SCHUERBEEK, N. ; NOMAN, M. ; RUTGEERTS, P. ; VERMEIRE, S.
Oxford, UK : Blackwell Science Ltd
Published 2005Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background : Infliximab treatment is effective in 70–80% of patients with refractory luminal and fistulizing Crohn's disease. The effect of infliximab is ascribed to induction of apoptosis.Aim : To study whether polymorphisms in apoptosis genes predict the response to infliximab and whether they interact with clinical predictors.Methods : Cohort of 287 consecutive patients treated with infliximab for refractory luminal (n = 204) or fistulizing (n = 83) Crohn's disease was genotyped for 21 polymorphisms in apoptosis genes. Short-term clinical response was assessed at week 4 (luminal Crohn's disease) or 10 (fistulizing Crohn's disease) after the first infliximab infusion.Results : The response rate was 69% in luminal and 80% in fistulizing Crohn's disease. In luminal Crohn's disease, two genetic predictors were identified: (i) patients with the Fas ligand −843 CC/CT genotype (n = 135) responded in 75%, with the TT genotype (n = 21) in 38% only (P = 0.002; OR = 0.11; 95% CI: 0.08–0.56). (ii) Patients with the caspase-9 93 TT (n = 9) genotype all responded, in contrast with 67% (n = 147) with the CC and CT genotype (P = 0.04; OR = 1.50; 95% CI: 1.34–1.68). Concomitant azathioprine/mercaptopurine therapy overcame the effect of unfavourable genotypes. In the fistulizing Crohn's disease cohort, the same Fas ligand −843 CC/CT genotype was the only predictor of response (P = 0.002; OR = 1.66; 95% CI: 1.21–2.29), interacting with caspase-9 93 polymorphism but not with azathioprine/mercaptopurine.Conclusion : We observed that polymorphisms in FasL/Fas system and caspase-9 influence the response to infliximab in luminal and fistulizing Crohn's disease. The strongest association was seen between the Fas ligand −843 TT genotype and non-response. Concomitant mercaptopurine/azathioprine therapy, however, was able to overcome the effect of unfavourable genotypes in luminal disease.Type of Medium: Electronic ResourceURL: -
10Articles: DFG German National LicensesStaff View
ISSN: 0303-7207Keywords: Insulin-like growth factor binding protein ; Leydig cell ; Paracrine interaction ; Peritubular cell ; Sertoli cell ; Somatomedin CSource: Elsevier Journal Backfiles on ScienceDirect 1907 - 2002Topics: BiologyMedicineType of Medium: Electronic ResourceURL: